Abstract:Abstract Background Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics. Significant intra- and inter-tumor heterogeneity and inadequate delivery of therapeutics across blood–brain barrier continue to be significant impediments towards developing therapies which can significantly enhance survival. We hypothesize that microRNAs have the potential to serve as effective therapeutics for glioblastoma as they modulate the activity of multiple signaling pathways, and hence can counteract heterogeneity if successfully delivered. Methods Using a computational approach, we identified microRNA-34a as a microRNA that maximally reduces the activation status of the three core signaling networks (the receptor tyrosine kinase, p53 and Rb networks) that have been found to be deregulated in most glioblastoma tumors. Glioblastoma cultures were transfected with microRNA-34a or control microRNA to assess biological function and therapeutic potential in vitro. Nanocells were derived from genetically modified bacteria and loaded with microRNA-34a for intravenous administration to orthotopic patient-derived glioblastoma xenografts in mice. Results Overexpression of microRNA-34a strongly reduced the activation status of the three core signaling networks. microRNA-34a transfection also inhibited the survival of multiple established glioblastoma cell lines, as well as primary patient-derived xenograft cultures representing the proneural, mesenchymal and classical subtypes. Transfection of microRNA-34a enhanced temozolomide (TMZ) response in in vitro cultures of glioblastoma cells with primary TMZ sensitivity, primary TMZ resistance and acquired TMZ resistance. Mechanistically, microRNA-34a downregulated multiple therapeutic resistance genes which are associated with worse survival in glioblastoma patients and are enriched in specific tumor spatial compartments. Importantly, intravenous administration of nanocells carrying miR-34a and targeted to epidermal growth factor receptor (EGFR) strongly enhanced TMZ sensitivity in an orthotopic patient-derived xenograft mouse model of glioblastoma. Conclusions Targeted bacterially-derived nanocells are an effective vehicle for the delivery of microRNA-34a to glioblastoma tumors. microRNA-34a inhibits survival and strongly sensitizes a wide range of glioblastoma cell cultures to TMZ, suggesting that combination therapy of TMZ with microRNA-34a loaded nanocells may serve as a novel therapeutic approach for the treatment of glioblastoma tumors.

Microrna-221 Targeting Pi3-K/Akt Signaling Axis Induces Cell Proliferation and Bcnu Resistance in Human Glioblastoma

miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.

Dnmt1 Mediates Chemosensitivity By Reducing Methylation Of Mirna-20a Promoter In Glioma Cells

miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase.

Mir-138-5p Suppresses Glioblastoma Cell Viability and Leads to Cell Cycle Arrest by Targeting Cyclin D3.

Mir-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells

MicroRNA-509-3p Inhibits Cell Proliferation and Invasion Via Downregulation of X-linked Inhibitor of Apoptosis in Glioma.

The Mir-92B Functions As a Potential Oncogene by Targeting on Smad3 in Glioblastomas

MicroRNA-16 Inhibits Glioma Cell Growth and Invasion Through Suppression of BCL2 and the Nuclear Factor-Κb1/mmp9 Signaling Pathway.

Exosomal Mir-221 Targets DNM3 to Induce Tumor Progression and Temozolomide Resistance in Glioma

MiR‐223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway

MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

MicroRNA-206 Inhibited the Progression of Glioblastoma Through BCL-2.

miR-92b regulates glioma cells proliferation, migration, invasion, and apoptosis via PTEN/Akt signaling pathway

Up-Regulation of microRNA-183 Promotes Cell Proliferation and Invasion in Glioma By Directly Targeting NEFL

Molecular Mechanism of Inhibition of Glioma by Targeting Autophagy Microtubule-Associated Protein 1A/1B-Light Chain 3 Family via miR-16 with Novel Liposome Nanoparticles

Microrna-149 Targets Caspase-2 in Glioma Progression

MicroRNA-873 (MiRNA-873) Inhibits Glioblastoma Tumorigenesis and Metastasis by Suppressing the Expression of IGF2BP1

MicroRNA 10a induces glioma tumorigenesis by targeting myotubularin-related protein 3 and regulating the Wnt/β-catenin signaling pathway.

MicroRNA-137 inhibits growth of glioblastoma through EGFR suppression.